Artivion (NYSE:AORT) CAO Amy Horton Sells 1,789 Shares of Stock

Artivion, Inc. (NYSE:AORT) CAO Amy Horton sold 1,789 shares of Artivion stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $44.62, for a total value of $79,825.18. Following the completion of the transaction, the chief accounting officer owned 144,862 shares of the company’s stock, valued at approximately $6,463,742.44. This represents a 1.22% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Artivion Trading Down 2.9%

Shares of NYSE:AORT traded down $1.37 during trading on Thursday, reaching $46.27. 46,541 shares of the company were exchanged, compared to its average volume of 432,117. The business’s fifty day simple moving average is $42.61 and its 200-day simple moving average is $35.96. The firm has a market capitalization of $2.19 billion, a PE ratio of -110.35 and a beta of 1.65. Artivion, Inc. has a 12-month low of $21.97 and a 12-month high of $48.04. The company has a debt-to-equity ratio of 0.52, a current ratio of 4.78 and a quick ratio of 3.48.

Artivion (NYSE:AORT) last issued its quarterly earnings data on Thursday, November 6th. The company reported $0.16 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.14 by $0.02. The firm had revenue of $113.39 million for the quarter, compared to the consensus estimate of $110.71 million. Artivion had a negative net margin of 4.43% and a positive return on equity of 5.70%. The business’s revenue was up 18.9% on a year-over-year basis. Artivion has set its FY 2025 guidance at EPS. On average, research analysts anticipate that Artivion, Inc. will post 0.37 EPS for the current year.

Institutional Investors Weigh In On Artivion

Several large investors have recently made changes to their positions in the business. Vanguard Group Inc. lifted its stake in shares of Artivion by 8.3% in the third quarter. Vanguard Group Inc. now owns 3,029,059 shares of the company’s stock worth $128,250,000 after acquiring an additional 232,424 shares in the last quarter. Wellington Management Group LLP grew its stake in Artivion by 4.1% during the 1st quarter. Wellington Management Group LLP now owns 1,727,408 shares of the company’s stock worth $42,460,000 after buying an additional 67,327 shares during the last quarter. Next Century Growth Investors LLC grew its position in Artivion by 107.6% in the 1st quarter. Next Century Growth Investors LLC now owns 1,022,775 shares of the company’s stock worth $25,140,000 after purchasing an additional 530,122 shares during the last quarter. Bank of America Corp DE raised its stake in Artivion by 22.8% during the 2nd quarter. Bank of America Corp DE now owns 645,070 shares of the company’s stock valued at $20,062,000 after acquiring an additional 119,634 shares in the last quarter. Finally, Invesco Ltd. raised its holdings in Artivion by 40.8% during the second quarter. Invesco Ltd. now owns 481,026 shares of the company’s stock worth $14,960,000 after purchasing an additional 139,370 shares in the last quarter. Institutional investors and hedge funds own 86.37% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on AORT shares. Citizens Jmp increased their price target on shares of Artivion from $47.00 to $53.00 and gave the company a “market outperform” rating in a research note on Friday, November 7th. Canaccord Genuity Group lifted their price target on shares of Artivion from $50.00 to $51.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. Oppenheimer reaffirmed an “outperform” rating and issued a $50.00 price target on shares of Artivion in a report on Friday, November 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Artivion in a report on Wednesday, October 8th. Finally, JMP Securities increased their price objective on Artivion from $42.00 to $47.00 and gave the stock a “market outperform” rating in a research report on Friday, October 10th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $49.11.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.